An Exeter Hospital hand surgeon's work is connecting carpal tunnel syndrome to a rare, life-threatening heart condition— and ...

US Transthyretin Amyloidosis Treatment Market Growth BURLINGAME, CA, UNITED STATES, March 13, 2025 /EINPresswire / -- The U.S. transthyretin a ...

In 2007, after 15 years of seeing numerous doctors and specialists, 15 years of misdiagnoses and 15 years of being viewed as a hypochondriac, on my birthday I was diagnosed with primary systemic AL am ...

Vutrisiran Market As per MRFR analysis, the Vutrisiran Market Growth Size was estimated at 0.62 (USD Billion) in 2024. US, NY, UNITED S ...

Erythropoietin-producing hepatocellular (Eph) receptors, including EphA4, are expressed on the cell surface and involved in brain development, which involves extensive pruning of synapses. A variant ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...

The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.

ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

“Today’s approval of WAINZUA in Europe offers adults with hereditary transthyretin-mediated amyloidosis with polyneuropathy a new, self-administered treatment option that provides consistent ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...